BG105531A - Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids - Google Patents
Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acidsInfo
- Publication number
- BG105531A BG105531A BG105531A BG10553101A BG105531A BG 105531 A BG105531 A BG 105531A BG 105531 A BG105531 A BG 105531A BG 10553101 A BG10553101 A BG 10553101A BG 105531 A BG105531 A BG 105531A
- Authority
- BG
- Bulgaria
- Prior art keywords
- methods
- triglyceride levels
- serum glucose
- reducing serum
- inhibiting angiogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11039598P | 1998-12-01 | 1998-12-01 | |
| PCT/US1999/028483 WO2000032180A2 (en) | 1998-12-01 | 1999-12-01 | Antihypertriglyceridemic, antihyperglycemic, anti-angiogenic and wound healing substituted indolealkanoic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105531A true BG105531A (en) | 2001-12-31 |
Family
ID=22332786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105531A BG105531A (en) | 1998-12-01 | 2001-05-22 | Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US6555568B1 (id) |
| EP (1) | EP1135124B1 (id) |
| JP (1) | JP2002531398A (id) |
| KR (1) | KR20010086075A (id) |
| CN (1) | CN1368883A (id) |
| AP (1) | AP2001002146A0 (id) |
| AT (1) | ATE265210T1 (id) |
| AU (1) | AU770925B2 (id) |
| BG (1) | BG105531A (id) |
| BR (1) | BR9915882A (id) |
| CA (1) | CA2385845A1 (id) |
| CZ (1) | CZ20011864A3 (id) |
| DE (1) | DE69916881T2 (id) |
| DZ (1) | DZ2953A1 (id) |
| EE (1) | EE200100296A (id) |
| HK (1) | HK1046372A1 (id) |
| HU (1) | HUP0104953A3 (id) |
| ID (1) | ID30037A (id) |
| IL (1) | IL143247A0 (id) |
| MX (1) | MXPA02003118A (id) |
| NO (1) | NO20012690L (id) |
| OA (1) | OA12035A (id) |
| PL (1) | PL349016A1 (id) |
| SK (1) | SK7352001A3 (id) |
| TN (1) | TNSN99224A1 (id) |
| TR (1) | TR200101539T2 (id) |
| TW (1) | TW584560B (id) |
| WO (1) | WO2000032180A2 (id) |
| YU (1) | YU40101A (id) |
| ZA (1) | ZA200104126B (id) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU59600A (sh) * | 1998-03-31 | 2002-12-10 | The Institute For Pharmaceutical Discovery Inc. | Supstituisane indolalkanoidske kiseline |
| TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| US6521659B2 (en) | 2000-03-02 | 2003-02-18 | Institute For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| WO2001085983A2 (en) * | 2000-05-09 | 2001-11-15 | The Institute For Pharmaceutical Discovery Llc | Methods for testing compounds useful for treating diabetic complications |
| WO2003000253A1 (en) | 2001-06-20 | 2003-01-03 | Wyeth | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| JP2006510672A (ja) | 2002-12-10 | 2006-03-30 | ワイス | プラスミノーゲン活性化因子の阻害因子−１（ｐａｉ−１）の阻害剤としての置換インドールオキソ−アセチルアミノ酢酸誘導体 |
| UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| DK1569900T3 (da) | 2002-12-10 | 2006-10-23 | Wyeth Corp | Substituerede 3-carbonyl-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1) |
| CN1723197A (zh) | 2002-12-10 | 2006-01-18 | 惠氏公司 | 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－烷基和3－芳基烷基1h－吲哚－1－基乙酸衍生物 |
| CN1723198A (zh) | 2002-12-10 | 2006-01-18 | 惠氏公司 | 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的芳基、芳氧基和烷氧基取代的1h－吲哚－3－基乙醛酸衍生物 |
| CA2523245C (en) * | 2003-04-28 | 2012-03-06 | Bayer Pharmaceuticals Corporation | Indole acetic acid derivatives and their use as pharmaceutical agents |
| US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
| US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
| US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
| US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
| US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
| US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
| US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
| US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
| US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| KR20070055563A (ko) | 2004-08-23 | 2007-05-30 | 와이어쓰 | 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산 |
| CA2588953A1 (en) * | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Ppar active compounds |
| WO2006060535A2 (en) * | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
| BRPI0614340A2 (pt) | 2005-08-17 | 2011-04-12 | Wyeth Corp | indóis substituìdos e métodos de seu uso |
| US20070072904A1 (en) * | 2005-09-07 | 2007-03-29 | Jack Lin | PPAR active compounds |
| NZ574375A (en) | 2006-07-22 | 2011-06-30 | Oxagen Ltd | 2-(5-fluoro-2-methyI-3-(2-(phenylsulfonyl)benzyl)-1H-indol-1-yl) acetic acid derivatives having CRTH2 antagonist activity |
| PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| MY155133A (en) | 2008-01-18 | 2015-09-15 | Atopix Therapeutics Ltd | Compounds having crth2 antagonist activity |
| US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| JP2011509990A (ja) | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| EP2970119B1 (en) * | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3557142A (en) | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
| IE47592B1 (en) | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| JPS55167282A (en) | 1979-06-12 | 1980-12-26 | Fujisawa Pharmaceut Co Ltd | Piperazine derivative or its salt and its preparation |
| US4283539A (en) | 1979-12-18 | 1981-08-11 | Pfizer Inc. | Isoquinoline acetic acids |
| US4363912A (en) | 1980-12-15 | 1982-12-14 | Pfizer Inc. | Indole thromboxane synthetase inhibitors |
| US4442118A (en) * | 1981-07-23 | 1984-04-10 | Ayerst, Mckenna & Harrison, Inc. | Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid |
| GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| IL80475A (en) | 1985-11-07 | 1993-01-31 | Pfizer | Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them |
| US4960785A (en) * | 1988-12-16 | 1990-10-02 | Pfizer Inc. | Indolinone derivatives |
| WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
| US4868301A (en) | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
| US5064852A (en) * | 1988-12-16 | 1991-11-12 | Pfizer Inc. | Indolinone derivatives |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| GB8916774D0 (en) * | 1989-07-21 | 1989-09-06 | Bayer Ag | New indole derivatives,a process for their preparation and their use in medicaments |
| US5304557A (en) | 1989-12-15 | 1994-04-19 | Pfizer Inc. | Substituted oxoophthalazinyl acetic acids and analogs thereof |
| US5312829A (en) * | 1990-05-21 | 1994-05-17 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives |
| US5236945A (en) | 1990-06-11 | 1993-08-17 | Pfizer Inc. | 1H-indazole-3-acetic acids as aldose reductase inhibitors |
| US5116753A (en) * | 1991-07-30 | 1992-05-26 | The Salk Institute For Biological Studies | Maintenance of pancreatic islets |
| GB9122590D0 (en) | 1991-10-24 | 1991-12-04 | Lilly Industries Ltd | Pharmaceutical compounds |
| JP3195455B2 (ja) | 1993-01-06 | 2001-08-06 | ウェルファイド株式会社 | キノリン−３−酢酸誘導体、その製造法と用途 |
| US5391551A (en) * | 1993-05-10 | 1995-02-21 | Pfizer Inc. | Method of lowering blood lipid levels |
| AU7634694A (en) | 1993-08-20 | 1995-03-21 | University Of Medicine And Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
| GB9317764D0 (en) * | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| TW401301B (en) * | 1994-10-07 | 2000-08-11 | Takeda Chemical Industries Ltd | Antihypertriglyceridemic composition |
| US5700819A (en) | 1994-11-29 | 1997-12-23 | Grelan Pharmaceutical Co., Ltd. | 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications |
| IL117208A0 (en) | 1995-02-23 | 1996-06-18 | Nissan Chemical Ind Ltd | Indole type thiazolidines |
| JPH09165371A (ja) | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
| YU59600A (sh) * | 1998-03-31 | 2002-12-10 | The Institute For Pharmaceutical Discovery Inc. | Supstituisane indolalkanoidske kiseline |
| TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| US6521659B2 (en) * | 2000-03-02 | 2003-02-18 | Institute For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
-
1999
- 1999-11-29 TN TNTNSN99224A patent/TNSN99224A1/fr unknown
- 1999-12-01 PL PL99349016A patent/PL349016A1/xx not_active Application Discontinuation
- 1999-12-01 CA CA002385845A patent/CA2385845A1/en not_active Abandoned
- 1999-12-01 WO PCT/US1999/028483 patent/WO2000032180A2/en not_active Application Discontinuation
- 1999-12-01 HU HU0104953A patent/HUP0104953A3/hu unknown
- 1999-12-01 YU YU40101A patent/YU40101A/sh unknown
- 1999-12-01 CZ CZ20011864A patent/CZ20011864A3/cs unknown
- 1999-12-01 SK SK735-2001A patent/SK7352001A3/sk unknown
- 1999-12-01 DE DE69916881T patent/DE69916881T2/de not_active Expired - Lifetime
- 1999-12-01 US US09/452,252 patent/US6555568B1/en not_active Expired - Fee Related
- 1999-12-01 IL IL14324799A patent/IL143247A0/xx unknown
- 1999-12-01 MX MXPA02003118A patent/MXPA02003118A/es not_active IP Right Cessation
- 1999-12-01 CN CN99814023A patent/CN1368883A/zh active Pending
- 1999-12-01 TR TR2001/01539T patent/TR200101539T2/xx unknown
- 1999-12-01 ID IDW00200101404A patent/ID30037A/id unknown
- 1999-12-01 BR BR9915882-5A patent/BR9915882A/pt not_active IP Right Cessation
- 1999-12-01 EE EEP200100296A patent/EE200100296A/xx unknown
- 1999-12-01 AP APAP/P/2001/002146A patent/AP2001002146A0/en unknown
- 1999-12-01 OA OA00100134A patent/OA12035A/en unknown
- 1999-12-01 AU AU21616/00A patent/AU770925B2/en not_active Ceased
- 1999-12-01 DZ DZ990253A patent/DZ2953A1/xx active
- 1999-12-01 JP JP2000584876A patent/JP2002531398A/ja active Pending
- 1999-12-01 EP EP99965955A patent/EP1135124B1/en not_active Expired - Lifetime
- 1999-12-01 KR KR1020017006865A patent/KR20010086075A/ko not_active Application Discontinuation
- 1999-12-01 AT AT99965955T patent/ATE265210T1/de not_active IP Right Cessation
-
2000
- 2000-02-01 TW TW088120912A patent/TW584560B/zh active
-
2001
- 2001-05-21 ZA ZA200104126A patent/ZA200104126B/en unknown
- 2001-05-22 BG BG105531A patent/BG105531A/xx unknown
- 2001-05-31 NO NO20012690A patent/NO20012690L/no not_active Application Discontinuation
-
2002
- 2002-11-02 HK HK02107989.6A patent/HK1046372A1/zh unknown
-
2003
- 2003-03-26 US US10/397,140 patent/US6964980B2/en not_active Expired - Fee Related
-
2005
- 2005-11-15 US US11/274,583 patent/US20060074114A1/en not_active Abandoned
-
2010
- 2010-08-30 US US12/871,304 patent/US20100324105A1/en not_active Abandoned
-
2011
- 2011-11-22 US US13/302,906 patent/US20120065203A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105531A (en) | Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids | |
| BRPI0007820B8 (pt) | formulações farmacêuticas agonistas de exendina e seus usos | |
| UA32636C2 (uk) | Засіб для зниження вмісту холестерину в сироватці крові людини | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
| AP2000001929A0 (en) | Substituted indolealkanoic acids. | |
| HUP0002373A2 (hu) | Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények | |
| ES2137948T3 (es) | Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina. | |
| FI883423A (fi) | Foerfarande foer framstaellning av terapeutisk anvaendbara piperazinylderivat av puriner. | |
| EP0693924A4 (en) | METHODS OF ADMINISTRATION -i (IN VIVO) OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED IN SUCH METHODS | |
| BR9205640A (pt) | Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares | |
| AU5988086A (en) | New carboxylic acid derivatives, processes for the preparation thereof, the use thereof and pharmaceutical compositions containing them | |
| WO2001064205A3 (en) | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | |
| AP2001002377A0 (en) | Substituted phenoxyacetic acids. | |
| AU8019898A (en) | Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome | |
| DE3263832D1 (en) | Gallium chloride, an anti-cancer drug | |
| WO2001051489A3 (en) | Methods for lowering uric acid levels | |
| DE69800210D1 (de) | Wasserfreies Mittel auf Lactulosebasis | |
| JO2296B1 (en) | Substituted pyrolates | |
| EP0261891A3 (en) | Pharmaceutical compositions containing etiochiolandione | |
| MY138338A (en) | Substituted indolealkanoic acids | |
| MY111342A (en) | Method and composition for treatment of patients having decompensated liver disease | |
| KR940008688A (ko) | 필수지방산에 의해 킬레이트화된 아연정제 | |
| IT1259140B (it) | Formulazioni farmaceutiche per la somministraziane orale di calcitonina | |
| UA36093A (uk) | Спосіб лікування хронічного бронхіту |